SUN PHARMA: Regulator Suspend Ophthalmic Production at Assam

: Regulators Suspend Ophthalmic Production at Assam Facility Over Quality Issues Drug regulatory authorities have ordered Sun Pharmaceutical Industries to discontinue the manufacturing, sale and distribution of eye-care products at its Assam unit after a joint inspection by CDSCO and state drug officials uncovered major quality-related shortcomings in August. KEY DEVELOPMENTS 🔹 Regulatory Restrictions: Authorities halted ophthalmic manufacturing and distribution after detecting serious gaps in quality-control procedures and bacterial contamination in sealed medicine bottles. 🔹 Product Withdrawal: The company had voluntarily recalled around 332 batches covering 11 eye-care brands in July as a precautionary step. 🔹 Products Under Scrutiny: The affected formulations include Lotepred 1%, Nepaflac OD, Nepaflac-Z, Brinzotim and Depopred. 🔹 Patient Safety: Reports of eye infections and contamination in unopened bottles have prompted increased regulatory examination of the company's sterile manufacturing standards. 🔹 Corrective Measures: Sun Pharma has filed a detailed corrective and compliance report, which is currently under regulatory assessment. Resumption of operations will depend on approval of the corrective measures. MARKET TAKEAWAY The regulatory intervention puts the spotlight on Sun Pharma's manufacturing practices, product quality and compliance framework. Investors will monitor regulatory developments, plant clearance and the possible financial implications. #SunPharma #SunPharmaceuticals #PharmaStocks #CDSCO #PharmaceuticalSector #DrugSafety #QualityControl #StockMarket #NSE #BSE #NiveshResearch Investment in securities market are subject to market risks. Read all the related documents carefully before investing.